In conclusion, OCOP, a novel metabolite of intestinal microflora of COP, notably ameliorated clinical manifestations, colonic injury, and inflammatory response against colitis, which was associated with the suppression of the NF-κB pathway and NLRP3 inflammasome as well as subsequent regulation of the imbalance between pro-inflammatory and anti-inflammatory mediators. This evidence concerns the gene NLRP3 and colitis.